Analysis of the main functions, mechanism of action and indications of Mavakaita (Maifantuo) capsules

Mavacamten is a new oral myocardial inhibitor, mainly used to treat patients with hypertrophic obstructive cardiomyopathy (HOCM). As the first drug approved to target HOCM, Mavaceta is a milestone in the field of cardiovascular diseases. This article will provide a detailed analysis from four aspects: mechanism of action, main efficacy, clinical indications and precautions for use.

First of all, the mechanism of action of Mavaceta is highly selective. HOCMThe main pathological characteristics of patients with HOCM are myocardial hypertrophy, smaller ventricular cavity and excessive myocardial contraction, leading to diastolic dysfunction and left ventricular outflow tract obstruction. Mavakatai reduces myocardial contractility by selectively inhibiting cardiac myosin ATP enzyme activity, thereby reducing left ventricular outflow tract obstruction pressure without significantly affecting the overall pumping function of the heart. This mechanism is different from traditional beta-blockers or calcium channel blockers, and can improve myocardial dysfunction from the root cause of the pathology and provide more precise treatment methods.

In terms of main efficacy, clinical studies have shown that Mavakatai can significantly improve HOCM patients’ exercise tolerance, cardiac function and symptom scores. Taking the two key clinical trials of EXPLORER-HCM and VALOR-HCM as examples, patients using Mavacartide saw a significant reduction in left ventricular outflow tract obstruction pressure, and at the same time, symptoms related to heart failure were relieved. The patient's 6 minute walking distance increased significantly, and the NYHA functional class improvement rate was higher than that of the control group. In addition, Mavacate improves cardiac structural parameters, including ventricular end-diastolic volume and left ventricular wall thickness, with potential benefits for long-term cardiac remodeling.

In terms of clinical indications, Mavaceta is mainly used for adult patients with HOCM, especially those with obvious symptoms or limited movement. According to the approved indication, its scope of use includes patients with left ventricular outflow tract gradient ≥50 mmHg or symptoms NYHA II-III. Drugs can be used as first-line targeted therapy or used in combination when beta-blockers and calcium channel blockers are ineffective. At the same time, for patients at high risk for surgery or interventional treatment, Mavaceta provides a non-invasive treatment option that reduces the need for surgical intervention.

In terms of precautions for use, Mavaceta should be taken strictly in accordance with the doctor's prescribed dosage, and cardiac function, especially left ventricular ejection fraction (LVEF), should be monitored regularly. In clinical trials, a small number of patients developed LVEFdecline or arrhythmia, the dose needs to be adjusted or discontinued in time. In addition, because it is a new targeted drug, pregnant women, lactating women and patients with severe liver and kidney dysfunction should use it with caution. Drug metabolism mainly relies on the liver's CYP2C19 and CYP3A pathways. The combined use of strong inhibitors or inducers may affect drug concentration and the dose needs to be adjusted.

To sum up, as the first myocardial-targeted drug for HOCM, Mavaceta can significantly improve left ventricular outflow tract obstruction, heart failure symptoms and exercise tolerance by virtue of its mechanism of selectively inhibiting myocardial contractility. Its main effect is to reduce obstructive pressure, improve cardiac structural remodeling and improve quality of life. It is suitable for adult patients with HOCM who have obvious symptoms or limited movement. Through standardized medication and close monitoring, Mavaceta provides a safe, efficient and non-invasive new treatment option for patients with hypertrophic obstructive cardiomyopathy, marking a new era of targeted therapy for cardiomyopathy.

Reference link:https://www.drugs.com